Efgartigimod治疗寻常型与落叶型天疱疮的II期可行性试验
这项开放标签II期适应性试验纳入34例轻中度寻常型或落叶型天疱疮患者,评估新生儿Fc受体抑制剂efgartigimod(10或25 mg/kg静脉给药)作为单药或联合低剂量泼尼松的疗效与安全性。
要点
- Efgartigimod 10或25 mg/kg静脉给药不良事件多为轻度,两剂量组谱相似。
- 28/31例(90%)在中位17天内获得早期疾病控制。
核心结论
- Efgartigimod耐受性良好,对天疱疮疾病活动度及结局指标显示出早期效应,支持进一步评估其作为天疱疮治疗的价值。
研究设计与样本
- 开放标签II期适应性试验,纳入34例轻中度寻常型或落叶型天疱疮患者。
- 序贯队列接受efgartigimod 10或25 mg/kg静脉给药,多种给药频率,作为单药或联合低剂量口服泼尼松。
- 主要终点为安全性,研究注册号NCT03334058。
主要发现
- 不良事件多为轻度,10 mg/kg组19例中16例(84%)报告,25 mg/kg组15例中13例(87%)报告,两组不良事件谱相似。
- 观察到血清总IgG及抗桥粒芯蛋白自身抗体大幅下降,并与PDAI评分改善相关。
- Efgartigimod单药或联合泼尼松使28/31例(90%)在中位17天后获得早期疾病控制。
临床怎么用
- 对于轻中度天疱疮患者,efgartigimod可作为单药或联合低剂量泼尼松实现早期疾病控制并减少激素依赖。
局限性
- 开放标签设计,样本量较小(34例),序贯队列多种给药方案,需进一步随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast-acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance. OBJECTIVES: To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus. METHODS: Thirty-four patients with mild-to-moderate pemphigus vulgaris or foliaceus were enrolled in an open-label phase II adaptive trial. In sequential cohorts, efgartigimod was dosed at 10 or 25 mg kg-1 intravenously with various dosing frequencies, as monotherapy or as add-on therapy to low-dose oral prednisone. Safety endpoints comprised the primary outcome. The study is registered at ClinicalTrials.gov (identifier NCT03334058). RESULTS: Adverse events were mostly mild and were reported by 16 of 19 (84%) patients receiving efgartigimod 10 mg kg-1 and 13 of 15 (87%) patients receiving 25 mg kg-1 , with similar adverse event profiles between dose groups. A major decrease in serum total IgG and anti-desmoglein autoantibodies was observed and correlated with improved Pemphigus Disease Area Index scores. Efgartigimod, as monotherapy or combined with prednisone, demonstrated early disease control in 28 of 31 (90%) patients after a median of 17 days. Optimized, prolonged treatment with efgartigimod in combination with a median dose of prednisone 0·26 mg kg-1 per day (range 0·06-0·48) led to complete clinical remission in 14 of 22 (64%) patients within 2-41 weeks. CONCLUSIONS: Efgartigimod was well tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus.
引用
- Goebeler M, Bata-Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2021. PMID: 34608631. doi:10.1111/bjd.20782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。